Vraylar, its ties with pregnancy, breastfeeding, and other related aspects
Vraylar and Pregnancy: Important Considerations
For individuals considering the use of Vraylar (cariprazine) during pregnancy, it's crucial to consult a healthcare professional first. This is because the safety of Vraylar during pregnancy has not been definitively established, and its use may potentially harm the fetus.
Exposure to Vraylar in the third trimester of pregnancy could lead to extrapyramidal symptoms and/or withdrawal symptoms in newborns. Extrapyramidal symptoms are drug-induced movement disorders, such as tremors or rigidity, similar to those seen with other antipsychotics. Withdrawal symptoms can manifest as irritability, tremors, or other signs consistent with neonatal adaptation syndrome.
Given the limited data available on the effects of cariprazine during lactation, the use of Vraylar during breastfeeding is often approached with caution or avoided until more information is available. It's also not known whether Vraylar passes into breast milk or can affect breast milk production.
Due to these potential risks, alternative treatments are often preferred during pregnancy and breastfeeding. Newborns exposed to Vraylar should be closely monitored after birth.
It's important to note that the drug information contained in this article is subject to change and should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional.
The Vraylar pregnancy registry collects health information about the effects of antipsychotics on pregnancy. If you're sexually active and you or your partner can become pregnant, it's advisable to discuss your birth control needs with your doctor while taking Vraylar.
For more information about the Vraylar pregnancy registry, visit the registry's website. Always remember, the best course of action is to consult with a healthcare professional when making decisions about medication use during pregnancy or breastfeeding.
